Clinical Scorecard: My One-Man Mission to Fix Liquid Biopsy

At a Glance

Key Highlights

• Bicycle PCR improves sensitivity in detecting low levels of cancer DNA.
• Addresses limitations of traditional PCR and blocking PCR methods.
• Validated through third-party testing and real patient samples.
• Achieved detection sensitivity of 0.02%, surpassing FDA-approved tests.
• Developed in response to personal experiences with cancer diagnostics, highlighting the emotional drive behind the innovation.

Guideline-Based Recommendations

Diagnosis

• Utilize Bicycle PCR for enhanced detection of cancer DNA in liquid biopsies, particularly in cases where traditional methods fall short.

Management

• Incorporate accurate molecular diagnostics to inform treatment decisions, considering the limitations of existing tests.

Monitoring & Follow-up

• Regularly assess the sensitivity and specificity of diagnostic tests, especially in light of the challenges faced by traditional PCR.

Risks

• Be aware of false positives in traditional PCR methods and the implications for patient management.

Patient & Prescribing Data

Individuals with a history of cancer or at high risk for recurrence.

Bicycle PCR can guide treatment decisions by accurately detecting cancer recurrence.

Clinical Best Practices

• Implement rigorous validation processes for new diagnostic technologies, including understanding the melting temperature concept.
• Ensure quality control measures are in place to differentiate between normal and cancer DNA.

References

• SentryDx